
JANSSEN CILAG LIMITED
JANSSEN CILAG LIMITED
1 Projects, page 1 of 1
Open Access Mandate for Publications and Research data assignment_turned_in Project2025 - 2030Partners:IPPOSI, UCB, MHRA, TRIAL NATION, THE SYNERGIST +50 partnersIPPOSI,UCB,MHRA,TRIAL NATION,THE SYNERGIST,BMS,INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA,FISABIO,Novo Nordisk,EDEX,AUH,Eli Lilly (United States),CHIESI,STICHTING EUPATI FOUNDATION,AbbVie,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.,SARD,PFIZER INC,TAK,NATIONAL CANCER INSTITUTE,AMGEN,ESPERITY,CENTRAL DENMARK EU OFFICE CDEU,UMC,SERGAS,Zabala Innovation Consulting (Spain),BIF,FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS,EUROPEAN PATIENTS FORUM,PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA,ECRIN,AU,VU,CDISC,JDRF,HL7 INTERNATIONAL,SYNERGIST SERVICES,Almirall (Spain),KLINIKUM DER UNIVERSITAET ZU KOELN,FSJD-CERCA,FUNDATIA YOUTH CANCER EUROPE,FOUNDATION 29,SHINE 2EUROPE LDA,EUC,Curewiki,VICOM,AstraZeneca (Sweden),EATG,JANSSEN CILAG LIMITED,SYNAPSE RESEARCH MANAGEMENT PARTNERS SL,DiCE,GLOBAL HEART HUB COMPANY LIMITED BY GUARANTEE,NOVARTIS,Social IT,Roche (Switzerland)Funder: European Commission Project Code: 101166227Overall Budget: 66,860,900 EURFunder Contribution: 31,538,000 EURThe public-private partnership, READI, seeks to help clinical studies (CS) to finally serve the complete general population, and therefore more patients. To date CS have struggled to recruit and retain participants from diverse backgrounds and communities, such as marginalized or disadvantaged groups (e.g., sexual, gender, age, cultural, and socioeconomic cohorts). The resulting knowledge gaps entrench or increase health disparities. The READI consortium strives to tackle these challenges by fostering a more cohesive and integrated CS ecosystem for underserved (US) and underrepresented (UR) communities. It will actively connect all key stakeholders who can facilitate access to a wide range of patient populations. It will provide these stakeholders with the necessary tools, training programs, and approaches essential for the recruitment and retention of US/UR patients in CS. In addition, it will design, build and implement a digital platform which is patient-centred, sustainable, open and innovative. This will foster improved access to CS information and READI tools, while also supporting patient connections with the created communities. Finally, at least 4 CS will be used for testing the effectiveness of the developed tools and approaches. READI has a three-fold objective: to help US/UR communities overcome CS participation barriers (e.g., lack of information/awareness, mistrust, poor communication, geographic limitations, prejudice), which in turn will improve research of many diseases and conditions, preventative care and treatment effectiveness in different demographic groups, and better serve society. READI’s success will draw from its interdisciplinary, multi-stakeholder, consortium composition of 73 organizations from 18 countries, with key expertise in drug development and CS (design and operations), engagement strategies for US/UR populations, digital platform development, training and capability building initiatives, effective communication and dissemination, long-term sustainability, ethics and regulatory affairs.
more_vert